Plus Therapeutics announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category III CPT code to track the utilization of convection‑enhanced delivery (CED) when used in the administration of REYOBIQ™ for patients with recurrent glioblastoma and pediatric brain cancer.
This milestone represents an important step in recognizing the clinical use of convection‑enhanced delivery in neuro‑oncology and supports the collection of real‑world data related to this specialized drug delivery approach.
Advancing Visibility for Innovative CNS Drug Delivery
Convection‑enhanced delivery is a targeted technique designed to deliver therapeutics directly into the brain, bypassing the blood–brain barrier and enabling localized administration within the central nervous system. CED has been studied for its potential to improve drug distribution within brain tumors while limiting systemic exposure.
The newly approved Category III CPT code is intended to facilitate the tracking of CED utilization when administering REYOBIQ™, helping to establish a clearer understanding of how this approach is used in clinical practice.
Supporting Data Collection and Future Evaluation
Category III CPT codes are temporary codes created to support emerging technologies, services, and procedures. They are commonly used to enable data collection, utilization tracking, and further clinical evaluation as innovative approaches continue to evolve.
By enabling standardized tracking of convection‑enhanced delivery in this setting, the new CPT code may help inform future clinical, economic, and health‑system assessments related to advanced CNS therapies.
Focus on High Unmet Need in Brain Cancer
Patients with recurrent glioblastoma and pediatric brain cancers face limited treatment options and poor prognoses, underscoring the urgent need for continued innovation in both therapeutics and delivery methods. Plus Therapeutics remains focused on advancing targeted radiotherapeutic approaches designed specifically for the challenges of treating cancers within the brain.
The approval of this CPT code reflects growing recognition of the importance of specialized delivery techniques in neuro‑oncology and aligns with the company’s broader commitment to thoughtful clinical development and patient‑centered progress.
Learn More
- Read the full press release: https://lnkd.in/gF6f5jpF
Plus Therapeutics will continue working with clinicians, researchers, and healthcare stakeholders to advance innovative approaches for patients with central nervous system cancers and to support the responsible adoption of emerging technologies in clinical care.
Recent Comments